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immunotherapy, interleukin 2, programmed death receptor-1, renal cell carcinoma, vaccine tumors. 9, 10 We have developed a technology that immobilizes SAtagged bioactive cytokines on the surface of biotinylated tumor cells to prepare tumor cell vaccines. This type of therapeutic vaccine not only maintains the biological activity of the cytokine but also contains all tumor antigens. [11] [12] [13] This type of therapeutic vaccine can induce specific antitumor T-cell responses, which could significantly delay tumor growth. However, this immunotherapy could not completely eradicate the tumor, and the therapeutic effect was usually restricted to the early stage of tumor growth. The limited therapeutic effect of this vaccination approach might be because vaccine-generated T cells become dysfunctional when they infiltrate into the TME. Immunity decreases with tumor growth because of tumor immune evasion existing in the TME. 14 Immune checkpoint blockade is a major advance in clinical immunotherapy. Blockade of PD-1/PD-L1 has shown therapeutic efficacy in the treatment of several advanced malignancies. 15, 16 Programmed death receptor-1/PD-L1 signaling plays a pivotal role in tumor immune evasion. or inducing T-cell death. 18 Several studies have reported a high level of PD-L1 expression in RCC. 19 PD-L1 expression in the TME is correlated with a poor prognosis. 20 Anti-PD-1 antibody has a specific therapeutic effect in treating RCC by rescuing dysfunctional T cells. However,
anti-PD-1 monotherapy could not induce a specific antitumor immune response. 21, 22 Cancer vaccine-based immunotherapy is a potential strategy to activate effector T-cell trafficking into the TME.
As a T-cell growth factor, IL-2 has been largely used to treat RCC in the past few years. 23 This study showed that SA-IL-2 surface-modified whole tumor cell vaccine could enhance tumor-specific cytotoxic Tlymphocyte activity and antitumor responses in vivo. However, PD-1/ PD-L1 signaling limited the therapeutic efficacy of SA-IL-2-modified vaccine. Therefore, we speculated that PD-1 blockade combined with tumor vaccine might hold greater potential for eliciting a strong specific immune response. In the present study, we evaluated the efficacy of a combination therapy involving the SA-IL-2 surface-modified tumor cells vaccine and PD-1 blockade in a RCC mouse model. This preclinical study may provide some experimental basis for applying this type of combination therapy in the treatment of human RCC.
| MATERIAL S AND ME THODS

| Animals and cells
Mouse renal tumor cell line Renca and mouse melanoma cell line B16-F10 (obtained from the American Type Culture Collection)
were stored at our laboratory. Cell lines were authenticated every 6-12 months. Renca cells were cultured in RPMI1640 (containing 10% FBS, 1% penicillin/streptomycin and 0.1% sodium pyruvate) in a 5% CO 2 humidified incubator. MycoplasmaOUT (Genloci, Nanjing, China) was used to protect the cells against mycoplasma contamination. SA-IL-2 and SA-GFP fusion proteins were prepared by our laboratory. BALB/C mice were purchased from the experimental animal center of Southern Medical University (Guangzhou, China). All animal experiments were carried out in accordance with relevant laws and institutional guidelines (Ethical number: L2016152). 
| Vaccine preparation
| Programmed death ligand-1 expression and PD-1 + CD8 + T-cell infiltration after SA-IL-2-modified vaccine therapy
On day 19 after tumor injection, tumor tissues were collected from each group. The frozen sections were fixed in cold acetone for 15 minutes and incubated with rabbit anti-mouse PD-L1 (eBioscience) or rabbit anti-mouse PD-1 (eBioscience) + rat anti-mouse CD8 PD-L1 in the TME were then observed through a fluorescence microscope (Eclipse E800; Nikon, Tokyo, Japan). 
| Combination therapy with SA-IL-2-modified vaccine and PD-1 blockade
| Specific immune response induced by combination therapy
Splenocytes were collected from the mice of each group on day 19 after tumor challenge. The splenocytes were cultured with inacti- To determine the specific immunity against Renca cells in vivo on day 60, the surviving mice in the combined group were injected s.c.
with 2 × 10 6 Renca cells (in the left hind leg) and melanoma cells (in the right hind leg), and tumor volume was recorded.
| Flow cytometry analysis of T-cell subsets after combination therapy
To determine the therapeutic effect of the SA-IL-2-modified vac- 
| Immunohistochemical analyses for tumor-infiltrating T lymphocytes
Tumor specimens were collected from each group on day 19 after tumor injection. All specimens were embedded in freezing medium. 
| Upregulation of PD-L1 expression induced by IFN-γ
To determine the role of IFN-γ in upregulating PD-L1 expression, Renca cells were cultured in the presence of IFN-γ (500 IU/mL) for 72 hours. Cells were then stained with PE-labeled anti-mPD-L1, and mean fluorescence intensity was measured by flow cytometry. (1 × 10 4 /mL in RPMI-1640 medium). Anti-mPD-1 antibody (eBscience) was used to block PD-1, with isotype IgG antibody as a control. CTL was assessed by the CytoTox 96 non-radioactive cytotoxicity assay (Promega).
| Statistics
FACS, ELISA, immunohistochemistry, and immunofluorescence data were analyzed using one-way ANOVA. Repeated measures analysis was used to compare the tumor volume among groups. All analyses were carried out using SPSS version 19.0 (SPSS Inc., Chicago, IL, USA), with P < .05 considered indicative of statistical significance.
| RE SULTS
| Anchoring efficiency and bioactivity of SA-IL-2 protein
Results of flow cytometry assay showed that 99.2% ethanol-fixed
Renca cells were anchored with SA-IL-2 fusion protein ( Figure 1A ). 
| Programmed death ligand-1 expression and PD-1 + CD8 + T-cell infiltration in TME after SA-IL-2-modified vaccine therapy
As shown in Figure 2 , expression of PD-L1 (red fluorescence) in the TME was upregulated after SA-IL-2-modified vaccine therapy. Although more CD8 + T cells (green fluorescence) infiltrated into the TME in the SA-IL-2-modified vaccine group than that in the other groups (P < .05), the number of PD-1 + CD8 + T cells (yellow fluorescence) also increased (P < .05), which eventually resulted in immune evasion.
| Programmed death receptor-1 blockade enhanced therapeutic efficacy of SA-IL-2-modified vaccine
We examined whether blocking PD-1 could augment the antitumor activity of the SA-IL-2-modified vaccine. According to the results, combination therapy with the SA-IL-2-modified vaccine and PD-1 blockade induced a stronger antitumor response, which significantly delayed tumor growth (P < .05; Figure 3A ) and reduced wet tumor weight (P < .05; Figure 3B ).
In the tumor-specific lymphocyte cytotoxicity assays, PD-1 blockade could enhance the tumor-specific cytotoxic activity induced by the SA-IL-2-modified vaccine ( Figure 3C) . Moreover, the SA-IL-2-modified vaccine combined with PD-1 blockade could effectively protect mice against a second set of Renca cells but not a melanoma cells challenge ( Figure 3D ), which also showed that PD-1 blockade combined with the SA-IL-2-modified vaccine could effectively enhance tumor-specific immune response.
| T-cell subsets after combination therapy with SA-IL-2-modified vaccine and PD-1 blockade
As shown in Figure 4A . All experiments were replicated at least three times (*P < .05, **P < .01). IL, interleukin | 37
combined group was the highest among the four groups ( Figure 4C ), suggesting that PD-1 blockade could rescue the tumor-infiltrating T lymphocytes generated by SA-IL-2-modified vaccine.
| Concentrations of IFN-γ, IL-4, IL-10 and IL-12 after combination therapy
Certain cytokines in vivo may reflect immune status. As shown in Figure 5 , the combined group had a higher concentration of IFN-γ than either the SA-IL-2-modified vaccine or PD-1 blockade alone.
Moreover, the combined group displayed the highest concentration of IL-12 (P < .05) but the lowest concentration of IL-10 among the four groups (P < .05). No significant difference in the concentration of IL-4 was found among the four groups (P > .05).
| Interferon-γ upregulated PD-L1 expression of tumor cells
To better study the effect of IFN-γ on the PD-L1 expression of tumor cells, we examined the PD-L1 expression of tumor cells after culturing with IFN-γ for 72 hours. Results showed that the PD-L1 expression of tumor cells was significantly upregulated (P < .05; Figure 6A ), supporting the important role of IFN-γ in promoting PD-L1 expression.
| Programmed death receptor-1 blockade enhanced tumor-specific cytotoxic activity
To test whether PD-1 blockade can augment specific antitumor ac- 
| D ISCUSS I ON
There is currently no effective treatment for recurrence of renal cell carcinoma. In the present study, we report a combination im- could enhance the antitumor effect by reversing immune evasion. 26 In this study, we explored whether blocking the PD-1/PD-L1 axis can optimize our strongly immunogenic but moderately efficacious vaccination platform.
Programmed death receptor-1/PD-L1 interaction inhibits the function and activity of effector T lymphocytes. 27 Upregulation of PD-L1 in the TME predicts poor prognosis in patients with cancer.
28
Blocking the PD-1/PD-L1 pathway has shown promising results in several carcinomas. 29 In this study, we showed that the TME highly A number of factors potentially affect the therapeutic effect of vaccines. 35 The present study has not evaluated the role of myeloid cells or stromal tissue in the combination therapy with the SA-IL-2-modified vaccine and PD-1 blockade. Further studies will be needed to evaluate the effect of tumor vaccine combined with blocking other immune checkpoints (anti-CTLA-4, anti-LAG3, anti-TIM3).
These studies can optimize the treatment of RCC in the future.
In conclusion, the SA-IL-2-modified vaccine can induce a tumor- All the experiments were replicated at least three times (*P < .05, **P < .01). IL, interleukin
